Latest News for: cd8 t cells

Edit

Mozart Therapeutics Presents Compelling New Preclinical Data on MTX-201 at the 2025 Crohn's and Colitis Congress®

Victoria Advocate 06 Feb 2025
Data demonstrate that MTX-201 binds CD8 Treg, selectively eliminates pathogenic CD4 T cells, and may decrease inflammation and reduce epithelial cell damage in IBD ....
Edit

Non Muscle Invasive Bladder Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism ...

GetNews 06 Feb 2025
It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products ... The attenuated IL-15 part of SIM0237 increases MTD and avoids overstimulation and accompanied anergy of NK and CD8+ T cells.
Edit

Covid Vaccination and Cancer

UK Column 30 Jan 2025
Fu and Jiang, in Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment, explore the complex interplay further and reveal the importance of dendritic cells in the role CD8 T cells play in fighting cancer.
Edit

Extensive-Stage SCLC Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by ...

GetNews 30 Jan 2025
The collaboration will evaluate etakafusp alfa (formerly known as AB248), Asher Bio’s investigational CD8+ T cell-targeted interleukin-2 (IL-2) immunotherapy, in combination with IMDELLTRA® ...
Edit

T cells rise up to fight infections in the gut

Science Daily 23 Jan 2025
Pathogen-fighting immune cells called tissue-resident memory CD8 T cells (TRM cells) go through a surprising transformation -- and relocation -- as they fight infections in the small intestine ... .
Edit

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

Pharmiweb 23 Jan 2025
FoxP3 T regulatory cells (Tregs) CD4+ and CD8+ central memory T cells CD14+ and CD14- monocytes Naïve B cells ... Activated T cells play an important role in the inflammatory process ... immune cell subsets.
Edit

Researchers identify T cells causing chronic sinus inflammation

ECNS 18 Jan 2025
A groundbreaking study published in Nature on Jan 16 uncovers a novel subset of memory CD8+ T cells, which are capable of "remembering" an antigen upon subsequent encounters, leading to a faster and more effective immune response.
Edit

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

Pharmiweb 10 Jan 2025
LYT-200 also synergizes with anti-PD-1 in activating CD4 and CD8 T cells in in vivo cancer models. LYT-200 is currently being evaluated in two ongoing Phase 1/2 adaptive design trials ...
Edit

Combination of Poolbeg and HOOKIPA Pharma Inc

Pharmiweb 02 Jan 2025
HOOKIPA's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases.
Edit

Great Anticancer Potential Comes in a Small Package 

The Scientist 28 Dec 2024
... cell surface ... We also evaluated changes in the tumor immune microenvironment and found that our treatment increased the percentage of CD8+ T cells and natural killer (NK) cells in the tumor tissues.
Edit

Cell Source Presents Potential Breakthrough in the Development of Off-the-Shelf CAR-T Cell Therapy at American ...

ACCESSWIRE 20 Dec 2024
"Our results help to unravel the mechanism by which anti-viral CD8 central memory veto cells overcome NK-mediated rejection of mismatched hemopoietic transplants," said study lead Dr.
Edit

Enterome’s Immunotherapy EO2463 Shows Early Clinical Response in Newly Diagnosed Follicular

Ottumwa Courier 10 Dec 2024
46% objective response rate, with 15% complete responses and ...
Edit

PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting

Pharmiweb 09 Dec 2024
LYT-200 also synergizes with anti-PD-1 in activating CD4 and CD8 T cells in in vivo cancer models. LYT-200 is currently being evaluated in two ongoing Phase 1/2 adaptive design trials for the ...

Most Viewed

×